NCT05642949View on ClinicalTrials.gov

Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

MHB036C

MHB036C will be administered intravenously at a frequency of once every 3 weeks (Q3W).

Trial Locations (3)

3144

Cabrini Health, Melbourne

4217

Pindara Private Hospital, Gold Coast

5042

Southern Oncology Clinical Research Unit, Adelaide

Sponsors
All Listed Sponsors
lead

Minghui Pharmaceutical Pty Ltd

INDUSTRY